Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Disulfides × Sarcoma × Clear all

Phase

Status

Completed 5 Active not recruiting 3 Withdrawn 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7 Genitourinary 4 Lymphoid 3 Other hematologic neoplasm 2 Head & Neck 2 Gynecologic 2 Gastrointestinal 2 Breast 2 Sarcoma 1 Plasma cell 1 Myeloid 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 24 Temozolomide 22 Doxorubicin 20 Radiotherapy 17 Filgrastim 16 Ifosfamide 13 Etoposide 13 Gemcitabine 12 Cisplatin 12 pazopanib 11 Irinotecan 11 Imatinib Mesylate 11 Bevacizumab 11 Carboplatin 10 Magnetic Resonance Spectroscopy 9 Granulocyte Colony-Stimulating Factor 9 Rituximab 8 Radiation 8 Docetaxel 8 Cyclosporine 8 fludarabine phosphate 7 Vincristine 7 Methotrexate 7 Melphalan 7 Busulfan 7 Antilymphocyte Serum 7 pembrolizumab 6 fludarabine 6 Radiotherapy, Intensity-Modulated 6 Paclitaxel 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00324987 2017-09-14

S0502

National Cancer Institute (NCI)

Phase 3 Terminated

12 enrolled 13 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡